Dasatinib

Generic Name: Dasatinib

Brand Names: Sprycel

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₆ClN_₇O_₂S

CAS Number: 302962-49-8

Unique Ingredient Identifier: X78UG0A0RN

Background: Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication: Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Phase 2

Recruiting

Conditions: Neuroblastoma

Interventions: Drug: Ceritinib
Drug: dasatinib
Drug: sorafenib
Drug: vorinostat
Drug: DFMO

First Posted Date: 2015-09-24

Last Posted Date: 2024-08-23

Lead Sponsor: Giselle Sholler

Target Recruit Count: 500

Registration Number: NCT02559778

Locations: 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
🇺🇸
St. Lukes, Boise, Idaho, United States
🇺🇸
Connecticut Children's Hospital, Hartford, Connecticut, United States

and more 23 locations

Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

Completed

Conditions: Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2015-09-11

Last Posted Date: 2017-07-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 101

Registration Number: NCT02546791

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Acute,Leukemia, Lymphoid

Interventions: Drug: Dasatinib
Drug: prednisone
Drug: cyclophosphamide
Drug: daunorubicin
Drug: vincristine
Drug: cytarabine
Drug: mercaptopurine
Drug: methotrexate
Drug: dexamethasone
Drug: mitoxantrone
Drug: etoposide
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2015-08-14

Last Posted Date: 2022-08-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 30

Registration Number: NCT02523976

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Ruxolitinib
Drug: Dasatinib
Drug: Dexamethasone

First Posted Date: 2015-07-10

Last Posted Date: 2024-07-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT02494882

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Breast Carcinoma
Cervical Carcinoma
Liver Carcinoma
Malignant Uterine Neoplasm
Recurrent Gastric Carcinoma
Recurrent Head and Neck Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Prostate Carcinoma
Recurrent Rectal Carcinoma

Interventions: Drug: Afatinib
Drug: Capivasertib
Drug: Binimetinib
Drug: Adavosertib
Procedure: Biospecimen Collection
Other: Cytology Specimen Collection Procedure
Drug: Afatinib Dimaleate
Drug: Dabrafenib
Drug: Defactinib
Drug: Fexagratinib
Drug: Dasatinib
Drug: Ipatasertib
Procedure: Biopsy
Drug: Crizotinib
Drug: Dabrafenib Mesylate
Drug: Taselisib
Drug: Sapanisertib
Drug: PI3K-beta Inhibitor GSK2636771
Drug: Defactinib Hydrochloride
Drug: Palbociclib
Biological: Nivolumab
Drug: Copanlisib
Drug: Ulixertinib
Biological: Trastuzumab Emtansine
Drug: Copanlisib Hydrochloride
Biological: Relatlimab
Procedure: Computed Tomography
Drug: Trametinib
Biological: Pertuzumab
Drug: Erdafitinib
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Drug: Larotrectinib
Procedure: Echocardiography
Drug: Osimertinib
Biological: Trastuzumab
Drug: Larotrectinib Sulfate
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Vismodegib
Drug: Sunitinib Malate
Procedure: Radionuclide Imaging

First Posted Date: 2015-06-08

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6452

Registration Number: NCT02465060

Locations: 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States

and more 1416 locations

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

Phase 2

Completed

Conditions: Cholangiocarcinoma

Interventions: Drug: Dasatinib

First Posted Date: 2015-04-29

Last Posted Date: 2020-07-31

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 8

Registration Number: NCT02428855

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
Recurrent Ph-Like Acute Lymphoblastic Leukemia
Refractory Ph-Like Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dasatinib
Drug: Dexamethasone
Drug: Doxorubicin
Other: Laboratory Biomarker Analysis
Drug: Leucovorin
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Prednisone
Biological: Rituximab
Drug: Ruxolitinib Phosphate
Drug: Vincristine

First Posted Date: 2015-04-20

Last Posted Date: 2024-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT02420717

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

Phase 1

Active, not recruiting

Conditions: Recurrent Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Refractory Brain Neoplasm
Recurrent Brain Neoplasm

Interventions: Drug: Cyclophosphamide
Drug: Dasatinib
Other: Laboratory Biomarker Analysis
Drug: Temsirolimus

First Posted Date: 2015-03-17

Last Posted Date: 2024-08-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT02389309

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Completed

Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions: Drug: Dasatinib

First Posted Date: 2015-03-17

Last Posted Date: 2017-09-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 128

Registration Number: NCT02389972

Locations: 🇨🇳
Local Institution, Wuhan, Hubei, China

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Phase 3

Completed

Conditions: Leukemia, Chronic Myeloid

Interventions: Drug: imatinib
Drug: nilotinib
Drug: dasatinib

First Posted Date: 2014-12-29

Last Posted Date: 2024-08-13

Lead Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Target Recruit Count: 229

Registration Number: NCT02326311

Locations: 🇮🇹
Policlinico Universitario di Milano, Milano, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy